Citations

Clear

1315 citation(s) found for "Kyle, RA".

Effect of surgery and chemotherapy on long-term survival in infants with congenital glioblastoma: an integrated survival analysis
Lu, Victor M. , O’Connor, Kyle P. , Siada, Ruby , Niazi, Toba N., Schwartz, Jonathan , Himes, Benjamin T., Brown, Desmond A., Nesvick, Cody L. , Siada, Ruby G, Himes, Benjamin , Brown, Desmond , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | August 14, 2020 | Volume: 26 | Issue: 5 | Pages: 563-571

10.3171/2020.5.peds20226 | PMID 32796143 Get It

OBJECTIVEGlioblastoma (GBM) during infancy is rare, and the clinical outcomes of congenital GBM are not well understood. Correspondingly, the aim of this study was to present a long-term survivor case from the authors’ institution, and establish an integrated cohort of cases across the published literature to better understand the clinical course of this disease in this setting.METHODSThe authors report the outcomes of an institutional case of congenital GBM diagnosed within the first 3 months of life, and performed a comprehensive literature search for published cases from 2000 onward for an integrated survival analysis. All cases were integrated into 1 cohort, and Kaplan-Meier estimations, Fisher’s exact test, and logistic regression were used to interrogate the data.RESULTSThe integrated cohort of 40 congenital GBM cases consisted of 23 (58%) females and 17 (42%) males born at a median gestational age of 38 weeks (range 22–40 weeks). Estimates of overall survival (OS) at 1 month was 67%, at 1 year it was 59%, and at 10 years it was 45%, with statistically superior outcomes for subgroups in which patients survived to be treated by resection and chemotherapy. In the overall cohort, multivariable analysis confirmed resection (p < 0.01) and chemotherapy (p < 0.01) as independent predictors of superior OS. Gestational age > 38 weeks (p < 0.01), Apgar scores ≥ 7 at 5 minutes (p < 0.01), absence of prenatal hydrocephalus (p < 0.01), and vaginal delivery (p < 0.01) were associated with greater odds of surgical diagnosis versus autopsy diagnosis.CONCLUSIONSCongenital GBM can deviate from the expected poor prognosis of adult GBM in terms of OS. Both resection and chemotherapy confer statistically superior prognostic advantages in those patients who survive within the immediate postnatal period, and should be first-line considerations in the initial management of this rare disease.
Building the vertebrate codex using the gene breaking protein trap library
Ichino, Noriko , Serres, MaKayla R., Urban, Rhianna , Urban, Mark D. , Treichel, Anthony J. , Schaefbauer, Kyle, Tallant, Lauren , Varshney, Gaurav K. , Skuster, Kimberly J., McNulty, Melissa S. , Daby, Camden L. , Wáng, Ying , Liao, Hsin‐Kai, El‐Rass, Suzan , Liu, Weibin , Anderson, Jennifer L. , Wishman, Mark , Sabharwal, Ankit , Schimmenti, Lisa A. , Sivasubbu, Sridhar , Balciunas, Darius , Hammerschmidt, Matthias , Farber, Steven , Wen, Xiao‐Yan , McGrail, Maura , Burgess, Shawn M. , Ekker, Stephen C. , Urban, Rhianna M , Schaefbauer, Kyle J., Tallant, Lauren E., Ding, Yonghe , Wishman, Mark D, Sabharwal, Ankit , Balciunas, Darius , Hammerschmidt, Matthias , Farber, Steven Arthur , Lin, Xueying , McGrail, Maura , Essner, Jeffrey , Burgess, Shawn M , Clark, Karl J , Ekker, Stephen C , Wen, Xiao-Yan , Schimmenti, Lisa A , Treichel, Anthony J , Ichino, Noriko , Xu, Xiaolei , Essner, Jeffrey J. , Clark, Karl J.

Mayo Clinic

eLife | August 11, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.54572 | PMID 32779569 Get It

One key bottleneck in understanding the human genome is the relative under-characterization of 90% of protein coding regions. We report a collection of 1200 transgenic zebrafish strains made with the gene-break transposon (GBT) protein trap to simultaneously report and reversibly knockdown the tagged genes. Protein trap-associated mRFP expression shows previously undocumented expression of 35% and 90% of cloned genes at 2 and 4 days post-fertilization, respectively. Further, investigated alleles regularly show 99% gene-specific mRNA knockdown. Homozygous GBT animals in ryr1b , fras1 , tnnt2a , edar and hmcn1 phenocopied established mutants. 204 cloned lines trapped diverse proteins, including 64 orthologs of human disease-associated genes with 40 as potential new disease models. Severely reduced skeletal muscle Ca 2+ transients in GBT ryr1b homozygous animals validated the ability to explore molecular mechanisms of genetic diseases. This GBT system facilitates novel functional genome annotation towards understanding cellular and molecular underpinnings of vertebrate biology and human disease.
Fair Play in Minnesota Hockey
Moris, Mae R. , Stuart, Michael J. , Farrell, Kyle , Caputi, Michelle H. , Smith, Aynsley M., Stuart, Michael J , Farrell, Kyle J , Krause, David A.

Mayo Clinic

Safety in Ice Hockey: 6th Volume | August 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: 102-107

10.1520/stp162520190051 Get It

Fair Play (FP) is a behavioral modification program originally created in Quebec, Canada, by Edmund Vaz when injuries, violence, aggressive infractions, and expense drastically decreased ice hockey registration numbers. He found that emphasizing sportsmanship had the potential to reduce dangerous plays. FP awards teams one additional point in the district standings after each game if the following criteria are met: (a) the team remained below the predetermined penalty minute threshold, (b) a coach was not assessed a game misconduct, and (c) none of the spectators were ejected from the arena. In collaboration with the Mayo Clinic, Minnesota Hockey adopted FP successfully in 2004. However, it was only applied to district games, accounting for just 36% of the games in a team's season. FP is currently a loosely recommended model in tournaments and plays no role in nondistrict games. In a study of two youth hockey tournaments, the tournament governed by intensified FP found significantly fewer head hits than the tournament without FP. Junior gold-level tournaments also experienced fewer injuries and concussions when using FP. Despite its established effectiveness, FP is underutilized by Minnesota Hockey. The Mayo Clinic Ice Hockey Research Team (MCIHRT) has therefore determined that FP requires a complete relaunch. The Minnesota Hockey board members, district leaders, and MCIHRT have agreed that increasing visibility and establishing universal application by Minnesota Hockey leadership are the most urgent needs. The MCIHRT action plan addressing shortcomings includes: (a) making a FP announcement before and after games; (b) publishing shortened, universal booklets solely regarding FP; (c) coordinating a distribution of new booklets to coaches, officials, and players/parents; and (d) creating webpages on all district and association sites including the rules of FP and access to the FP standings. Finally, creative ways to increase FP's power to favorably modify behavior will be solicited.
Transient Complete Heart Block After Alcohol Septal Ablation
Cha, Yong‐Mei , Klarich, Kyle W. , Rihal, Charanjit S. , Eleid, Mackram F. , El-Sabawi, Bassim, Bradley, David J. , El‐Sabawi, Bassim , Nishimura, Rick A. , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | August 6, 2020 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/circinterventions.120.009202 | PMID 32757660 Get It

The authors reply
Bohman, J. Kyle , DeMartino, Erin S. , Bohman, John Kyle, Bohman, John K

Mayo Clinic

Critical Care Medicine | August 4, 2020 | Volume: 48 | Issue: 10 | Pages: e986-e987

10.1097/ccm.0000000000004529 | PMID 32931199 Get It

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
Abdallah, Nadine , Greipp, Patricia T. , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Buadi, Francis K. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Siddiqui, Mustaqeem , Lust, John A., Kyle, Robert A. , Bergsagel, Leif, Kumar, Shaji , Bergsagel, P. Leif , Bergsagel, P. Leif , Gertz, Morie A , Buadi, Francis K , Siddiqui, Mustaqeem A , Dingli, David , Greipp, Patricia T , Lin, Yi , Dispenzieri, Angela , Baughn, Linda B. , Go, Ronald S. , Leung, Nelson , Ketterling, Rhett P. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | August 4, 2020 | Volume: 4 | Issue: 15 | Pages: 3509-3519

10.1182/bloodadvances.2020002218 | PMID 32750129 Get It

Abstract A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities in multiple myeloma (MM). It is unclear whether +1q is independently associated with decreased overall survival (OS). The objective of this study was to evaluate the impact of +1q on clinical characteristics, treatment response, and survival outcomes. We included 1376 Mayo Clinic patients diagnosed with MM from 2005 to 2018 who underwent fluorescence in situ hybridization testing at diagnosis with a panel including the +1q probe. A gain in 1q was found in 391 patients (28%) and was associated with anemia, hypercalcemia, high tumor burden, International Staging System (ISS) stage 3, high-risk (HR) translocations, and chromosome 13 abnormalities. There was no difference in overall response or deeper responses to proteasome inhibitor (PI)–, immunomodulatory drug (iMiD)–, or PI plus IMiD–based induction. Time to next treatment was shorter in patients with +1q compared with those without +1q (19.9 vs 27.7 months; P &lt; .001). On univariate analysis, +1q was associated with increased risk of death (risk ratio [RR], 1.9; P &lt; .001), and decreased OS was seen in all treatment groups. +1q was independently associated with decreased OS on multivariate analysis when other HR cytogenetic abnormalities, ISS stage 3, and age ≥70 years were included (RR, 1.5; P &lt; .001). Gain of &gt;1 copy of 1q was not associated with worse OS compared with gain of 1 copy (4.9 vs 4.3 years; P = .21). +1q was associated with high tumor burden, advanced disease stage, and HR translocations. It is independently associated with decreased OS, even in the setting of novel therapy and transplant.
SIRT7‐mediated modulation of glutaminase 1 regulates TGF‐β‐induced pulmonary fibrosis
Choudhury, Malay , Yin, Xueqian , Schaefbauer, Kyle, Kang, Jeong Han , Leof, Edward B. , Schaefbauer, Kyle J., Kottom, Theodore J. , Roy, Bhaskar, Limper, Andrew H.

Mayo Clinic

The FASEB Journal | July 27, 2020 | Volume: 34 | Issue: 7 | Pages: 8920-8940

10.1096/fj.202000564r | PMID 32519817 Get It

Abstract In the current work we show that the profibrotic actions of TGF‐β are mediated, at least in part, through a metabolic maladaptation in glutamine metabolism and how the inhibition of glutaminase 1 (GLS1) reverses pulmonary fibrosis. GLS1 was found to be highly expressed in fibrotic vs normal lung fibroblasts and the expression of profibrotic targets, cell migration, and soft agar colony formation stimulated by TGF‐β required GLS1 activity. Moreover, knockdown of SMAD2 or SMAD3 as well as inhibition of PI3K, mTORC2, and PDGFR abrogated the induction of GLS1 by TGF‐β. We further demonstrated that the NAD‐dependent protein deacetylase, SIRT7, and the FOXO4 transcription factor acted as endogenous brakes for GLS1 expression, which are inhibited by TGF‐β. Lastly, administration of the GLS1 inhibitor CB‐839 attenuated bleomycin‐induced pulmonary fibrosis. Our study points to an exciting and unexplored connection between epigenetic and transcriptional processes that regulate glutamine metabolism and fibrotic development in a TGF‐β‐dependent manner.
Revisiting the temporal artery posterior auricular skin flap with an anatomical basis stepwise pedicle dissection for use in targeted facial subunit reconstruction
Ganry, Laurent , Ettinger, Kyle S. , Rougier, Guillaume , Qassemyar, Q. , Fernandes, Rui , Qassemyar, Quentin

Mayo Clinic

Head & Neck | July 20, 2020 | Volume: 42 | Issue: 11 | Pages: 3153-3160

10.1002/hed.26362 | PMID 32686883 Get It

AbstractBackgroundThis study demonstrates the anatomy of the pedicled temporal artery posterior auricular skin (TAPAS) flap, its variable arc of rotation based on stepwise dissection, and case reports demonstrating clinical use. This flap provides excellent color match and ultrathin tissue for targeted reconstruction of small‐ to medium‐sized facial subunit defects.MethodsTwenty‐six cadaver dissections were performed. The authors measured the reach and rotation limits of the flap in a pedicled fashion depending on a stepwise approach for vascular pedicle dissection. Two clinical cases demonstrating maximum arc of rotation are seen.ResultsThe pedicled TAPAS flap maximal rotation limits allow for reconstruction of facial subunits encompassing nearly the entire ipsilateral face. No venous congestion, wound complications, or partial/total flap loss were encountered with extreme clinical applications.ConclusionThe pedicled TAPAS flap has extensive versatility for reconstruction of a variety of facial subunit defects. The flap also has, in theory, multiple applications for intraoral reconstruction.
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio
Muchtar, Eli , Gertz, Morie A. , Lacy, Martha Q. , Leung, Nelson , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Warsame, Rahma , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Russell, Stephen J. , Lust, John A., Siddiqui, Mustaqeem , Kyle, Robert A. , Kumar, Shaji , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Hwa, Yi Lisa, Russell, Stephen, Rajkumar, S Vincent , Dispenzieri, Angela , Gertz, Morie A , Leung, Nelson , Muchtar, E , Russell, Stephen J , Siddiqui, Mustaqeem A , Dingli, David , Buadi, Francis K. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | July 18, 2020 | Volume: 95 | Issue: 11 | Pages: 1280-1287

10.1002/ajh.25940 | PMID 32681737 Get It

AbstractResponse assessment in light chain (AL) amyloidosis is based on serum and urine monoclonal protein studies. Newly diagnosed patients (n = 373) who achieved very good partial response or complete response (CR) to first line therapy were assessed for the survival impact of each of the monoclonal protein studies. At end of therapy (EOT), negative serum/urine immunofixation (IFE) was achieved in 61% of patients, 72% achieved normal serum free light chain ratio (sFLCR), and the median involved free light chain (iFLC) and difference between involved to uninvolved light chain (dFLC) were 17 mg/L and 5 mg/L, respectively. Overall, 46% of patients achieved a CR at EOT. At EOT, iFLC ≤20 mg/L and dFLC ≤10 mg/L were additive in survival discrimination to negative serum/urine IFE and were independent predictors of overall survival. In contrast, normalization of sFLCR did not add survival discrimination to serum/urine IFE and was not independent predictor of survival. We propose a new definition for hematological CR to include serum/urine IFE negativity plus iFLC ≤20 mg/L or dFLC ≤10 mg/L, instead of the current definition of serum/urine IFE negativity and normal sFLCR. Complete response using dFLC ≤10 mg/L had the best performance in those with significant renal dysfunction and by light chain isotype, making it the preferred partner to IFE. Validation of these results in a multicenter cohort is warranted.
Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma
Abraham, Roshini S. , Clark, Raynell, Bryant, Sandra C. , Lymp, James, Larson, Timothy , Kyle, Robert A. , Katzmann, Jerry A.

Mayo Clinic

Clinical Chemistry | July 17, 2020 | Volume: 48 | Issue: 4 | Pages: 655-657

10.1093/clinchem/48.4.655 Get It